Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk said on Friday its popular weight-loss drug Wegovy will cost 301.91 euros ($338.35) for four weeks of treatment at the highest dose in Germany, as the Danish drugmaker prepares for a market launch in Europe's largest pharmaceutical market at the end of this month.

Novo Nordisk says German 4-week Wegovy at highest dose to cost 302 euros

Eli Lilly

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.

Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs

Genmab - ADR

Vertex Pharmaceuticals

Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks.

3 Biotech Stocks That AI is Loving in July

A media report detailed the lack of staying power of weight loss drugs. Novo Nordisk has gained fame and popularity as the developer of one of those, Wegovy.

Why Novo Nordisk Stock Sank on Tuesday

The European Medicines Agency didn't specify which additional GLP-1 drugs are now being investigated, but it could potentially include Eli Lilly's Mounjaro.

EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs

The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used to treat Type 2 diabetes and obesity. The review comes after Iceland's medical regulator reported self-injury and suicidal thoughts in people using Ozempic, Saxenda and Wegovy.

EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

The European Medicines Agency on Tuesday said it was extending the review of possible suicidal thoughts after use of Novo Nordisk's drugs Ozempic and Saxenda, to include other diabetes and weight-loss drugs in the same class.

EU extends Ozempic probe to include other drugs

Ginkgo Bioworks Holdings

Ginkgo Bioworks (NYSE: DNA ) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk (NYSE: NVO ). These two companies have been working together on the development of expression systems for pharmaceutical products.

DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership

Two drugs used as diabetes and weight-loss treatments are being investigated after some patients reported having suicidal thoughts.

Weight-loss and diabetes drugs investigated over reports of suicidal thoughts

Novo Nordisk, a global healthcare company, is expected to see significant growth due to its focus on Anti-Obesity Medication and novel GLP-1 therapies, particularly semaglutide-based medications Ozempic, Rybelsus, and Wegovy. Despite current supply constraints, the company's growth potential is high due to the increasing global prevalence of obesity and type 2 diabetes and the expected production increase from a new plant in Clayton, North Carolina. While the company's valuation is high, there is still opportunity for investors to onboard at a fair price.

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Rapid-weight-loss shot Ozempic, which is manufactured by pharmaceutical company Novo Nordisk, is being probed by European drug-safety regulators after two users reported thoughts of suicide.

Ozempic faces review over concerns it may trigger suicidal thoughts

The Danish pharma giant finds itself under scrutiny once again- this time, from European regulators.

EU Investigates Ozempic Maker After Reports Of Suicidal Thoughts

Ozempic is under review by European drug-safety regulators after they received reports of suicidal thoughts linked to the popular weight-loss drug and another medicine in the class.

Europe Is Probing Whether Ozempic Use Raises Risk of Suicidal Thoughts

Danish firm Novo Nordisk says "patient safety is a top priority" following reports.

European regulator to review weight-loss drugs following reports of suicidal thoughts

Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus.

Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs

It has been hugely popular for weight loss even though it's not approved for that use. The drug's potential could go far beyond just weight loss and diabetes, however.

Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher

Patients taking diabetes and weight loss drugs during anesthesia may be at increased risk of serious complications like nausea and vomiting, the ASA said.

People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says

Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors said in a report Thursday. A decades-old law generally prohibits Medicare from covering prescription drugs for weight loss.

Medicare coverage of weight-loss drugs? Don't count on it, analysts say.

Altimmune

Amgen

Pfizer

Viking Therapeutics

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

Factbox: Weight-loss drugs: the next gold rush

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Eli Lilly Sets New Bar In Weight Loss And Nears Record High; Novo Nordisk Slips

Akero Therapeutics Inc

89bio Inc

Madrigal Pharmaceuticals

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.

Weight-loss drugs in development aim to replace injections with pills

Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.

Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data

Novo Nordisk's pill is an oral version of semaglutide, the active ingredient in the Danish company's blockbuster weight loss injections Ozempic and Wegovy.

News for Novo Nordisk Stock (NVO)